It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

Fragile X Syndrome Treatment with MC01CI Study

Clinical Trial Title: 
A six-week, randomized, multicenter, double-blind, parallel, flexed- and fixed-dose study of MC01CI (Metadoxine Extended-Release) 700 mg and 1400 mg compared with placebo in adults and adolescents with fragile X syndrome
Clinical Trial Protocol ID: 
14050601
Clinical Trial Protocol Description: 

The purpose of this study is to evaluate the effects of the investigational drug metadoxine extended release (MDX) on attention deficit symptoms. Attention deficit is a common symptom often associated with fragile X syndrome.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Be between ages 15 and 55.
  • Be available for 84 days (12 weeks), including follow-up examinations.

This is a partial list of inclusion criteria.

Clinical Trial Area: 
Fragile X Syndrome
Contact Phone: 
(312) 942-7250
Contact Name: 
Crystal Hervey